Background Treatment options for patients suffering from progressive forms of multiple sclerosis (MS) remain inadequate. Mast cells actively participate in the pathogenesis of MS, in part because ...

Rese-cel, previously called CABA-201, is a CAR T-cell therapy that's designed to treat MS by depleting B-cells.

While MS isn’t fatal on its own, accompanying complications can shorten life. That said, treatment can significantly decrease the chance of a shortened life span. When it comes to the outlook ...

Switching therapies is a common part of multiple sclerosis management and may be considered for several reasons.

Up to 85% of the people who receive a diagnosis of the neurodegenerative disorder multiple sclerosis (MS) have the ...

Subcutaneous ocrelizumab (SC OCR) was found to be safe for patients with relapsing and primary progressive multiple sclerosis ...

Decades of subtle health changes went by without answers. When worsening disability led Roger to a multiple sclerosis (MS) ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

NICE changes its mind on Novartis drug Mayzent for progressive multiple sclerosis, making it an option for up to 38,000 people with the disease in the UK ...

NDAQ:TGTX) TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated ...